Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 586.27% | Truist Securities | $8 → $7 | Maintains | Buy |
| 08/14/2023 | 390.2% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 880.39% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 292.16% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 782.35% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 488.24% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 684.31% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 390.2% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 47.06% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 1370.59% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 1468.63% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 1174.51% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 1370.59% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 1860.78% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 390.2% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 1762.75% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 2056.86% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 1468.63% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 2350.98% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 1860.78% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 2056.86% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 1272.55% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 978.43% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 978.43% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/15/2023 | 586.27% | 信托证券 | 8 美元 → 7 美元 | 维护 | 购买 |
| 08/14/2023 | 390.2% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 08/11/2023 | 880.39% | Wedbush | 16 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 08/10/2023 | 292.16% | 富国银行 | 5 美元 → 4 美元 | 维护 | 超重 |
| 08/09/2023 | 782.35% | 巴克莱 | 11 美元 → 9 美元 | 维护 | 超重 |
| 08/09/2023 | 488.24% | 加拿大皇家银行资本 | 8 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/10/2023 | 684.31% | 信托证券 | 16 美元 → 8 美元 | 维护 | 购买 |
| 05/01/2023 | 390.2% | HC Wainwright & Co. | 15 美元 → 5 美元 | 维护 | 购买 |
| 04/28/2023 | 47.06% | B of A 类证券 | 5 美元 → 1.5 美元 | 降级 | 中性 → 跑赢大盘 |
| 03/03/2023 | 1370.59% | HC Wainwright & Co. | 25 美元 → 15 美元 | 维护 | 购买 |
| 02/27/2023 | 1468.63% | Wedbush | → 16 美元 | 升级 | 中性 → 跑赢大盘 |
| 02/23/2023 | 1174.51% | 加拿大皇家银行资本 | 22 美元 → 13 美元 | 维护 | 跑赢大盘 |
| 2023 年 4 月 1 日 | 1370.59% | 富国银行 | 20 美元 → 15 美元 | 维护 | 超重 |
| 2022 年 7 月 11 日 | 1860.78% | 富国银行 | 22 美元 → 20 美元 | 维护 | 超重 |
| 06/13/2022 | 390.2% | Wedbush | → 5 美元 | 假设 | → 中立 |
| 2022 年 5 月 4 日 | 1762.75% | 信托证券 | 23 美元 → 19 美元 | 维护 | 购买 |
| 2021 年 4 月 5 日 | 2056.86% | 加拿大皇家银行资本 | → 22 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 01/06/2021 | 1468.63% | Stifel | → 16 美元 | 启动覆盖开启 | → 按住 |
| 2020 年 12 月 16 日 | 2350.98% | HC Wainwright & Co. | → 25 美元 | 假设 | → 购买 |
| 2020 年 8 月 9 日 | 1860.78% | B of A 类证券 | → 20 美元 | 恢复 | → 购买 |
| 2020 年 7 月 7 日 | 2056.86% | SunTrust 罗宾逊汉弗莱 | → 22 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 6 月 22 日 | 1272.55% | HC Wainwright & Co. | 16 美元 → 14 美元 | 维护 | 购买 |
| 11/14/2018 | 978.43% | 摩根大通 | 35 美元 → 11 美元 | 维护 | 中立 |
| 11/14/2018 | 978.43% | 摩根大通 | 35 美元 → 11 美元 | 降级 | 超重 → 中性 |
| 11/09/2018 | — | 古根海姆 | 降级 | 买入 → 中性 |
What is the target price for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的目标价格是多少？
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Truist Securities on August 15, 2023. The analyst firm set a price target for $7.00 expecting SGMO to rise to within 12 months (a possible 586.27% upside). 14 analyst firms have reported ratings in the last year.
Truist Securities于2023年8月15日公布了Sangamo Therapeutics（纳斯达克股票代码：SGMO）的最新目标股价。该分析公司将目标股价定为7.00美元，预计SGMO将在12个月内上涨至586.27％（可能上涨586.27％）。去年有14家分析公司公布了评级。
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
分析师对Sangamo Therapeutics（SGMO）的最新评级是多少？
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Truist Securities, and Sangamo Therapeutics maintained their buy rating.
Sangamo Therapeutics（纳斯达克股票代码：SGMO）的最新分析师评级由Truist Securities提供，Sangamo Therapeutics维持其买入评级。
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Sangamo Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Sangamo Therapeutics的最后一次评级是在2023年8月15日提交的，因此你应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
分析师对 Sangamo Therapeutics (SGMO) 的评级正确吗？
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a maintained with a price target of $8.00 to $7.00. The current price Sangamo Therapeutics (SGMO) is trading at is $1.02, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Sangamo Therapeutics（SGMO）评级保持不变，目标股价为8.00美元至7.00美元。Sangamo Therapeutics（SGMO）目前的交易价格为1.02美元，超出了分析师的预期区间。